Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01105208
Recruitment Status : Completed
First Posted : April 16, 2010
Last Update Posted : May 20, 2014
Corporación Bonima S.A. de C.V.
Information provided by (Responsible Party):

Brief Summary:
A single dose, two treatments (two cephalexin suspension brands), two sequences, cross-over design was used with a washout of 7 days between the two study periods. Treatment groups balanced with the same number of healthy volunteers who were randomly (in two strata: male and female) assigned to the study drug administration sequences

Condition or disease Intervention/treatment Phase
Anti-Infective Agents Drug: Cephalexin suspension (Optocef, BAYO5448 ) Drug: Cephalexin suspension (Keflex) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef From Bayer (Cephalexin Suspension 250 mg/5 mL and Equivalent Concentration of Keflex Pediatrico From Eli Lilly (Cephalexin Suspension 125 mg/5mL) in Healthy Subjects Under Fasting Conditions
Study Start Date : March 2010
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm 1 Drug: Cephalexin suspension (Optocef, BAYO5448 )
Single dose of 500 mg / 10 mL

Active Comparator: Arm 2 Drug: Cephalexin suspension (Keflex)
Single dose of 500 mg / 20 mL

Primary Outcome Measures :
  1. Least square estimator of average maximum plasmatic concentration (log transformed) [ Time Frame: After two months ]
  2. Least square estimator of area under the pharmacokinetic curve (log transformed) [ Time Frame: After two months ]

Secondary Outcome Measures :
  1. Time at which maximum concentration is reached [ Time Frame: After two months ]
  2. Area under the pharmacokinetic curve from time=0 to last blood sample [ Time Frame: After two months ]
  3. Clearance constant of plasmatic concentrations of study drug [ Time Frame: After two months ]
  4. Half life of plasmatic concentration of study drug [ Time Frame: After two months ]
  5. Adverse events collection [ Time Frame: Up to 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male or female volunteers age between 18 and 55 years old with normal vital signs, electrocardiogram (ECG), blood chemistry, liver function profile and urinalysis

Exclusion Criteria:

  • History of illnesses or any organic abnormalities that could affect the results of the study
  • History of abuse tobacco or alcohol or regular use of recreational or therapeutic drugs
  • Subjects that have taken any medication within 14 days or that are in an elimination period of less than 7 half-lives (whichever is longest) before study startup.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01105208

Morelia, Michoacán, Mexico, 58256
Sponsors and Collaborators
Corporación Bonima S.A. de C.V.
Study Director: Bayer Study Director Bayer

Additional Information:
Responsible Party: Bayer Identifier: NCT01105208     History of Changes
Other Study ID Numbers: 15188
Biocef-S ( Other Identifier: Company Internal )
First Posted: April 16, 2010    Key Record Dates
Last Update Posted: May 20, 2014
Last Verified: May 2014

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents